Drugs / Choline
Choline
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05880849 | Jun 2023 → Jul 2025 | Alzheimer disease | Paul E Schulz | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01149538 | Jul 2010 → Sep 2014 | fetal alcohol syndrome, neurobehavioral disorder with prenatal alcohol exposure, partial fetal alcohol syndrome | University of Minnesota | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05076682 | Jun 2022 → Dec 2026 expected | triple-negative breast carcinoma | Fudan University | Recruiting | Met primary |
| Phase 2 | NCT00031135 | Sep 2001 → Sep 2005 | liver disorder | Northwestern University | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06910943 | Dec 2025 → Jun 2027 expected | choline deficiency disease, liver disorder | Protara Therapeutics | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06527391 | Aug 2025 → Sep 2027 expected | iron deficiency anemia | University of Minnesota | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01934777 | Oct 2013 → Oct 2014 | NAFLD1, abdominal obesity-metabolic syndrome, fibrotic liver disease, obesity disorder | Bambino Gesù Hospital and Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT01371357 | May → Dec 2011 | hyperhomocysteinemia | Center for Health Sciences, Serbia | Completed | No outcome recorded |
| Phase 43 trials · 1 missed | ||||||
| Phase 4 | NCT01749982 | Dec 2012 → Mar 2013 | — | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT01098383 | Mar 2010 → Dec 2017 | autism | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00720343 | Feb 2009 → Jun 2011 | — | Columbia University | Completed | Missed primary |
| Phase not applicable3 trials | ||||||
| — | NCT03312140 | Nov 2014 → Apr 2016 | cystic fibrosis-related liver disease | University Hospital Tuebingen | Completed | No outcome recorded |
| — | NCT00686361 | Oct 2007 → Aug 2010 | cystic fibrosis | University of British Columbia | Completed | No outcome recorded |
| — | NCT00004697 | Nov 1997 → Mar 1999 | fatty liver disease | University of Texas | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 0 | NCT01731236 Comparator | Feb 2011 → Dec 2027 expected | — | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06379971 Comparator | Nov 2024 → Apr 2029 expected | — | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT03028857 Comparator | Jun 2017 → Dec 2025 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT00332124 Comparator | Jun 2006 → Mar 2017 | pregnancy disorder | University of Colorado, Denver | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Choline | “different dietary agents were used in the past for the treatment of elevated total plasma homocysteine (T-HCy), e. g. betaine, choline (betaine precursor) or folic acid.” NCT01371357 ↗ |
| Known as | Choline Chloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03312140 ↗ |
| Known as | Choline Chloride for Injection | “Choline Chloride for Injection (study drug)” NCT06910943 ↗ |
| Action | Activate | “Choline activates fetal α7-nicotinic acetylcholine receptors” PMID 23318559 ↗ Mar 2013 |
| Modality | Other / unclassified | “dietary phosphatidylcholine supplementation” PMID 23318559 ↗ Mar 2013 |
| Route | Oral | “high-dose oral phosphatidylcholine supplementation during pregnancy” PMID 26651393 ↗ Dec 2015 |